Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumab), the first and only approved biologic therapy that selectively blocks only IL-23. The DERM 2017 NP/PA CME Conference has concluded in Las Vegas. Valeant is selling its Obagi Medical Products division for $190 million in cash to a Chinese investment group.